EXOSC2

Across TCGA pan-cancer cohorts, EXOSC2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated EXOSC2 data layer compared with 27 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher EXOSC2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated EXOSC2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LSCC show a favorable association.

PDAC, COAD, and CCRCC are the cancer types where EXOSC2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	III,IV	0.355	0.895	<.001	39	view →
COAD	DFS	Median	IV	0.432	0.944	.012	18	view →
CCRCC	OS	Tertile	All	1.000	0.617	.003	14	view →
LSCC	DFS	Median	II,III,IV	0.856	0.520	.005	9	view →
HNSC	OS	Median	III,IV	0.798	0.566	.009	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

EXOSC2–PDAC (DFS)

Open the PDAC breakdown →